PCM
NRXP icon

Penserra Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Penserra Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,016
Closed -$6K – 1138
2022
Q2 		$6K Buy
1,016
+375
+59% +$4.93K ﹤0.01% 1342
2022
Q1 		$15K Buy
641
+329
+105% +$10.7K ﹤0.01% 1332
2021
Q4 		$14K Buy
312
+16
+5% +$1.16K ﹤0.01% 1262
2021
Q3 		$27K Buy
+296
New +$38.5K ﹤0.01% 1202

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Penserra Capital Management's NRXP Position: Q3 2022 in Review

Penserra Capital Management sold out of NRX Pharmaceuticals (NRXP) in Q3 2022, closing a stake of 1,016 shares — an estimated $6K sold.

Penserra Capital Management first reported a position in NRXP in Q3 2021 and held it in 4 quarters. The position peaked at $27K in Q3 2021. 30 funds tracked by Wall St. Rank hold NRXP as of Q3 2022.

  • Penserra Capital Management reported no remaining NRX Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 1,016 NRX Pharmaceuticals shares in Q3 2022, an estimated $6K.
  • Penserra Capital Management first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Penserra Capital Management's NRX Pharmaceuticals position peaked at $27K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.